- NASDAQ: BNGO has soared by 14% on Tuesday to $12.16.
- BioNano Genomics announced publication of a study on DNA methylation.
- BNGO is one of the best performing stocks of 2021.
Update: BNGO shares are trading higher on Tuesday as the company announced that its "Saphyr Study Is First to Analyze Cancer Regulation at Level of Single DNA Molecules, Opens Promising New Avenue of Cancer Research".
Going from strength to strength – BioNano Genomics (NASDAQ: BNGO) has surged by 28.73% on Monday, closing at $12.58. While shares are off the fresh 52-week highs of $13.65 and may continue correcting on Tuesday, the surge is an incredible feat for the firm. San Diego-based Bioano hit a 52-week low of $0.25 late last year, making its leap even more impressive.
The genetics company impressed the medical community and investors with its recent breakthroughs including mapping genes related to the autism spectrum, cancer, and even COVID-19. Its work allows for better care and may also translate into higher sales down the road.
Investors were impressed enough to provide the company with $230 million in its underwritten offering of common stock. The financial exercise includes options to buy more stocks at a discounted price. The prospects of offering new stock had already weighed on BNGO earlier in the year, and closing the round was shrugged off on Monday.
Raising money became easier when professional investors also gave BioNano Genomics some backing. Jason McCarthy, an analyst with Maxim, bumped up his price forecast from $2 to $14. At the current closing price, there is still room for the company to run. McCarthy was impressed by the firm's Next-Generation Cytogenomics Symposium – an event where it showcased its Saphyr optical genome mapping (OGM) capabilities.
BNGO stock price
NASDAQ: BNGO has already dropped from the highs and may continue lower. However, such a correction makes sense after the meteoric rise. To the downside, the levels to watch are the round $12 level and then Monday's low of $10.45.
Looking up, Monday's close at $12.58 is followed by $13 and then by $13.65, the 52-week high. McCarthy's price forecast of $14 is next in line.
Best Stocks to Buy Forecast 2021: Vaccines and zero rates to broaden recovery
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD holds steady near 0.6250 ahead of RBA Minutes
The AUD/USD pair trades on a flat note around 0.6250 during the early Asian session on Monday. Traders brace for the Reserve Bank of Australia Minutes released on Tuesday for some insight into the interest rate outlook.
USD/JPY consolidates around 156.50 area; bullish bias remains
USD/JPY holds steady around the mid-156.00s at the start of a new week and for now, seems to have stalled a modest pullback from the 158.00 neighborhood, or over a five-month top touched on Friday. Doubts over when the BoJ could hike rates again and a positive risk tone undermine the safe-haven JPY.
Gold price bulls seem non-committed around $2,620 amid mixed cues
Gold price struggles to capitalize on last week's goodish bounce from a one-month low and oscillates in a range during the Asian session on Monday. Geopolitical risks and trade war fears support the safe-haven XAU/USD. Meanwhile, the Fed's hawkish shift acts as a tailwind for the elevated US bond yields and a bullish USD, capping the non-yielding yellow metal.
Week ahead: No festive cheer for the markets after hawkish Fed
US and Japanese data in focus as markets wind down for Christmas. Gold and stocks bruised by Fed, but can the US dollar extend its gains? Risk of volatility amid thin trading and Treasury auctions.
Bank of England stays on hold, but a dovish front is building
Bank of England rates were maintained at 4.75% today, in line with expectations. However, the 6-3 vote split sent a moderately dovish signal to markets, prompting some dovish repricing and a weaker pound. We remain more dovish than market pricing for 2025.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.